drugset
drugset / Trial / NCT02222987

Influence of Clopidogrel on the Pharmacodynamics and Safety of Terbogrel in Healthy Male Subjects

NCT02222987 ↗

Phase 1 Completed 14 enrolled Boehringer Ingelheim
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Study to assess the influence of 75 mg clopidogrel on the pharmacodynamics and safety of 100 mg terbogrel bid.

Timeline

Start
1999-02
Primary completion
1999-03
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Clopidogrel Small molecule 75 mg —
Subject Terbogrel Small molecule 100 mg —

Indications

No indication recorded.